CORONA Remedies Limited has successfully commenced the additional commercial production of tablet(s)/ apsule(s) at the Bhayla manufacturing facility of the company today. As on March 31, 2025, the facility has an installed capacity of 852.80 million with the available capacity of 600 million and actual production of 561.49 million which is equivalent to capacity utilization of 93.58%.

The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility.

The additional commercial production will add a significant milestone in the company's strategic expansion to augment the upcoming market demands, enhance the in-house production capabilities and improve the supply chain agility.

The commercialized additional capacity is entirely being funded through internal accruals.